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Titanocene compounds are a novel series of agents that exhibit cytotoxic effects in a variety of human cancer cells in vitro and in vivo.
In this study, the antiproliferative activity of two titanocenes (Titanocenes X and Y) was evaluated in human epidermoid cancer cells
in vitro. Titanocenes X and Y induce apoptotic cell death in epidermoid cancer cells, with IC50 values that are comparable to cisplatin.
Characterisation of the cell death pathway induced by titanocene compounds in A431 cells revealed that apoptosis is preceded by
cell cycle arrest and the inhibition of cell proliferation. The induction of apoptosis is dependent on the activation of caspase-3 and -7
but not caspase-8. Furthermore, the antitumour activity of Titanocene Y was tested in an A431 xenograft model of epidermoid
cancer. Results indicate that Titanocene Y significantly reduced the growth of A431 xenografts with an antitumour effect similar to
cisplatin. These results suggest that titanocenes represent a novel series of promising antitumour agents.
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Cisplatin is one of the most effective chemotherapeutic
agents known, displaying clinical activity against a wide range of
human tumours, including cancer of the ovary, testis, bladder,
lung, head and neck, cervix and endometrium and as a second-line
therapy in the treatment of breast cancer (Farrell et al, 2004). The
cytotoxic effect of cisplatin is thought to be mediated by its
interaction with DNA to form DNA adducts and intrastrand
crosslink adducts, which activate several signal transduction
pathways that culminate in the induction of apoptotic cell death
(Siddik, 2003).
Despite the success of cisplatin in the treatment of cancer,
it is frequently associated with severe toxicity, such as severe
nausea, vomiting, diarrhoea, renal and nerve toxicity. However,
despite this, the antineoplastic effects of cisplatin has gene-
rated much interest in developing new organometallic complexes
with reduced toxicity and improved clinical activity (Reedijk,
2003). This led to the development of alternative transition
metal-based anticancer drugs (Farrell et al, 1999; Gelasco and
Lippard, 1999; Jamieson and Lippard, 1999); however, success in
this area has been slow. One such group, the metallocene
dichlorides show remarkable antitumour activity (Ko ¨pf-Maier
and Ko ¨pf, 1987, 1998); however, unfortunately, the efficacy of
titanium dichloride (Cp2TiCl2) in phase II clinical trials in patients
with metastatic renal (Lummen et al, 1998) or breast cancer
(Kro ¨ger et al, 2000) was too low to pursue. This highlights
the requirement for additional agents in the treatment and
management of human cancer. In recent years, combination
regimens involving cisplatin and microtubule-disrupting agents
have been explored, and initial results demonstrate improved
response rates over single therapy regimens (Rose et al, 1999;
Sawada et al, 2003).
Apoptosis can occur through a number of signalling pathways
broadly classified as the extrinsic and intrinsic cascades. A
common component of these two pathways is a family of cysteine
proteases known as caspases that become activated following
cleavage by upstream activators. Caspases activate downstream
substrates ultimately leading to the regulated dismantling of the
cell. This tightly regulated process differs greatly from necrotic cell
death, which occurs as a result of non-specific cell injury. In this
case, the cells swell and eventually rupture releasing their contents
into the surrounding tissue, and thereby eliciting an inflammatory
response (Vermeulen et al, 2005).
Ansa-Titanocenes are a novel series of drugs synthesised from
titanium dichloride and fulvenes (Teuber et al, 1997; Hartl et al,
2001; Tacke et al, 2001b; Siddik, 2003) that contain highly
substituted ethylene bridge (Tacke et al, 2001a, 2004; Rehmann
et al, 2005). The subsequent synthesis of unbridged titanocene
analogues led to increased cytotoxicity, suggesting a promising
structure–function activity of these compounds (Sweeney
et al, 2005, 2006). Two members of this series, [1,2-di(cyclopenta-
dienyl)-1,2-di-(4-N,N-dimethylaminophenyl)ethanediyl] titanium
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sdichloride and bis-[(p-methoxybenzyl)cyclopentadienyl] titaniu-
m(IV) dichloride, known as Titanocenes X and Y, respectively
(Figure 1), display antiproliferative and cytotoxic effects in a
variety of tumour cells. The antiproliferative activity of Titano-
cenes X and Y was studied in 36 human tumour cell lines and
compared to cytotoxicity induced by the conventional agent
cisplatin (Kelter et al, 2005). It was found that the highly
substituted titanocenes are as effective as cisplatin at inducing
cell death against a broad range of human tumours, and in
some cases, titanocenes displayed greater cytotoxicity than
cisplatin. Titanocenes significantly reduce growth of ex vivo
tumour explants (Oberschmidt et al, 2005) and reduce tumour
growth in vivo (Fichtner et al, 2006; Valadares et al, 2006;
Beckhove et al, 2007). Collectively, these reports suggest the
potential of highly substituted titanocenes as novel anticancer
agents in single or combination treatment regimens and for
treatment of cisplatin-resistant tumours. However, to date, the
mechanism of action of titanocenes remains unknown, and
further studies are required to improve our understanding of the
precise mechanism of action of these novel compounds. This is
essential to progress the search and development of new
antitumour drugs.
We have investigated cell cycle and cell death alterations
induced by titanocenes in HeLa cervical epithelial carcinoma cells
and in the A431 human epidermoid carcinoma cell line. We have
found that cell cycle alterations lead to the activation of caspases
and cell death through apoptosis. This provides valuable insights
into the mechanism of action of novel titanocene agents.
Furthermore, we report encouraging in vivo results that further
highlight the potential of substituted titanocenes for the treatment
of cancer.
MATERIALS AND METHODS
Materials
[1,2-Di(cyclopentadienyl)-1,2-di-(4-N,N-dimethylaminophenyl)
ethanediyl] titanium dichloride (Titanocene X), bis-[(p-methoxybenzyl)
cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) and
Cp2TiCl2 were obtained from UCD School of Chemistry and
Chemical Biology (Dublin, Ireland). The caspase-3, -7 and -8
antibodies were from Cell Signalling Technologies (Danvers, MA,
USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
b-actin antibodies were from Sigma-Aldrich (Dublin, Ireland).
Unless otherwise stated, all other chemicals were purchased from
Sigma-Aldrich. Annexin V/FITC antibody was from BD Bio-
sciences, Oxford, UK. The HeLa cervical carcinoma cell line and
the A431 carcinoma cell line were purchased from the American
Tissue Culture Collection, LGC Promochem, Middlesex, UK.
Methods
Growth inhibition assay HeLa and A431 cells (1 10
4) were
seeded in 0.1ml growth medium (MEM supplemented with 10%
FCS, 2mML-glutamine and 100mgml
 1 penicillin/streptomycin) in
a 96-well plate and incubated overnight at 371C. Cells were treated
with vehicle (0.5% (v/v) DMSO), or either Titanocene X,
Titanocene Y, Cp2TiCl2 and cisplatin in a concentration range of
2.5 10
 4–5 10
 8 M and incubated at 371C for 24 and 48h. A
volume of 20ml of MTT solution (3-(4,5-dimethylthiazol-2-yl)-2-5-
diphenyltetrazolium bromide) (5mgml
 1 in PBS) was added, and
plates were incubated at 371C in the dark for 4h. Growth medium
was removed and replaced with DMSO (200ml) to dissolve the blue
formazan crystals formed. Results were recorded spectrophoto-
metrically at 540nm.
Cell cycle profile HeLa and A431 cells (1 10
6) were treated with
the indicated compounds and incubated at 371C. Following
treatment the cells were harvested by trypsination, washed in
PBS and fixed overnight in ethanol (70% (v/v)) at 41C. Following
incubation, the ethanol was removed and the cells were
resuspended in PBS (400ml). RNase A (10mgml
 1) was added
and DNA was stained with propidium iodide (0.2mgml
 1 in PBS)
and incubated in the dark at 371C for 30min. The DNA content of
10000 cells was analysed by Flow cytometry.
Annexin V and propidium iodide staining A431 cells (0.8 10
6)
were treated with the indicated compounds and incubated at 371C.
Following treatment, the cells were harvested by trypsination
and centrifugation at 1000r.p.m. for 5min. The supernatant was
removed, and the cell pellet was washed in PBS followed by two
washes in binding buffer (10mM HEPES, 150mM NaCl, 5mM KCl,
1.8mM CaCl2,1 m M MgCl2). The cells were incubated with an
Annexin V/FITC antibody (5ml in 100ml binding buffer) and
incubated at 41C for 15min in the dark. Samples were washed in
binding buffer, and the supernatant was discarded. The pellet was
resuspended in 490ml binding buffer and 10ml propidium iodide
(10mgml
 1 in PBS) was added to the samples before analysis by
flow cytometry.
A431 xenografts The in vivo experiments consist of three groups
of mice treated with co-solvent, Titanocene Y and cisplatin,
respectively. A431 cells (1 10
7) were injected subcutaneously
(s.c.) into female NMRI:nu/nu mice (eight mice per group).
Tumours reached a palpable size of 5–6mm diameter before
treatment was initiated. Titanocene Y was dissolved in DMSO
(final concentration 10%) and diluted with 0.5% Tween 80 in
saline. The mixture was injected intraperitoneally (i.p.) at a dose of
40mgkg
 1day
 1 (predetermined) once daily for 5 consecutive
days. One group of mice was treated with solvent (negative
control), whereas the remaining group was treated with cisplatin
(Medac GmbH, Hamburg, Germany) at a dose of 3mgkg
 1day
 1
for 5 consecutive days. Tumour size was measured using callipers,
and tumour volume and relative tumour volume (in relation to the
first treatment day) in the three experimental groups was
calculated. Body weight and morbidity of the mice were
determined continuously during the experiments for an estimation
of tolerability. The animal experiment was performed according to
the German Animal Protection Law and with approval from the
responsible authorities. The in vivo procedures were consistent
and in compliance with the UKCCCR guidelines.
Western blotting A431 cells (1 10
6) were treated with the indi-
cated compounds as outlined. The cells were harvested by trypsi-
nation and centrifugation at 1000r.p.m. for 5min. The resulting
pellet was washed in PBS and lysed in 100ml urea lysis buffer
(7 M urea, 2 M thiourea, 2% CHAPS, 1% DTT, 0.8% pharmalyte, one
tablet of complete protease inhibitors (per 20ml lysis buffer) and
Ti
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Figure 1 Molecular structures of Titanocenes X and Y.
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sincubated on ice for 10min followed by centrifugation for 5min at
13000r.p.m. to pellet cell debris. Protein content was determined
using a Bradford assay. Protein was resolved by SDS–PAGE,
transferred onto PVDF membrane and blocked overnight at 41Ci n
TBS containing 5% (w/v) dried milk followed by incubation with
primary antibody for 1h at room temperature. The membrane was
washed with TBS containing 0.1% (w/v) Tween 20 and incubated
with horseradish peroxidase-conjugated secondary antibody for
1h and enhanced chemiluminescence was used to visualise the
proteins.
RESULTS
Dose- and time-dependent cytotoxic effect of titanocene
compounds in HeLa and A431 cells
The in vitro cytotoxicity of Titanocenes X and Y, Cp2TiCl2 and
cisplatin was determined in HeLa and A431 cells. Cells were treated
with 0.5, 5.0, 50 or 250mM of each drug for up to 48h. Results
shown in Figure 2 outline that all compounds induced a varying
degree of cytotoxicity in HeLa and A431 cells. Importantly, it was
found that Titanocene X-induced cytotoxicity was greater than that
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IC50 values ± s.e of Cp2TiCl2, cisplatin, titanocene X and titanocene Y on HeLa and A431 cells.
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IC50 mol l–1 ± s.e
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Figure 2 Antiproliferative effect of Titanocenes X and Y, Cp2TiCl2 and cisplatin on HeLa and A431 cells. HeLa (A and B) and A431 (C and D) cells were
treated with vehicle (DMSO (0.5% v/v)) or 0.5, 5, 50 and 250mM of the indicated compound for 24h (A and C) and 48h (B and D). Cell viability was
determined using an MTT assay and absorbance was monitored spectrophotometrically at 540nm. Results represent the mean±s.e.m. of three separate
experiments. (E) IC50 values±s.e. from Cp2TiCl2, cisplatin, Titanocenes X and Y treatment of HeLa and A431 cells for 48h, calculated using the PRISM
statistical analysis software package.
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sinduced by Cp2TiCl2 and similar to that induced by cisplatin in the
two cell lines. Titanocene Y-induced cytotoxicity was significantly
greater than that observed following Cp2TiCl2 treatment and
similar to cisplatin in cells, however, Titanocene Y induced greater
cytotoxic effect than both Cp2TiCl2 and cisplatin in A431 cells. The
IC50 values have been calculated for each compound based on
48-h survival assays (Figure 2E). Cp2TiCl2 has an IC50 value of
424 10
 6moll
 1 when tested on the HeLa cells, whereas
cisplatin, Titanocenes X and Y have significantly lower IC50
values of 41 10
 6,6 7 10
 6 and 40 10
 6moll
 1, respectively.
Cp2TiCl2 has an IC50 value of 157 10
 6moll
 1 in A431 cells,
whereas cisplatin and Titanocene X have similar IC50 values of
137 10
 6 and 123 10
 6moll
 1, respectively. However, Titano-
cene Y induced significantly greater loss in cell viability in this cell
line over Titanocene X, cisplatin and Cp2TiCl2, with an IC50 value
of 39 10
 6moll
 1. Loss of cell viability was observed with 0.5mM
Titanocene Y. This data may highlight an important cytotoxic
advantage of Titanocene Y over the traditionally used cisplatin in
cancer treatment.
Titanocene Y efficiently reduces A431 xenograft growth
in vivo
In this study, we found that Titanocene Y is more potent than
Titanocene X at inducing cell death of HeLa and A431 cancer cells
in vitro. We have expanded the study to an in vivo xenograft A431
mouse model using the more potent compound, Titanocene Y, and
we compared the effects observed to cisplatin when treated at
their respective maximum tolerable dose, which we have
previously determined as 40mgkgday
 1 and 3mgkg
 1day
 1,
respectively (Fichtner et al, 2006). Three groups of mice consisting
of eight mice each were treated i.p. with solvent, Titanocene Y
(40mgkg
 1day
 1) or cisplatin (3mgkgday
 1) for 5 consecutive
days, and tumour size was measured twice weekly for 3 weeks. As
shown in Figure 3A, Titanocene Y induced a significant inhibition
of tumour growth, with 40% inhibition in mean tumour volume
following drug treatment in comparison to control animals. From
this study, it is apparent that Titanocene Y is as good as cisplatin at
delaying growth of A431 xenografts in vivo. The tumour growth
in the mice treated with cisplatin displayed a similar trend with a
41% reduction of mean tumour volume detected following drug
treatment in comparison to control animals. In the two mice
cohorts treated with Titanocene Y and cisplatin, a moderate body
weight loss was observed, representing 8 and 5%, respectively
(Figure 3B).
Titanocene Y induces apoptotic cell death in A431 cells
Cisplatin has been shown to induce apoptotic cell death in human
cancer cells, including A431 cells (Gonzalez et al, 2001; Cummings
and Schnellmann, 2002; Sawada et al, 2003). To investigate the
mechanism by which Titanocene Y induces cell death, A431 cancer
cells were stained with Annexin V and propidium iodide to detect
early and late apoptotic cells. Vehicle-treated cells contained negli-
gible levels (3%) of apoptotic cells, whereas treatment with Titano-
cene Y and cisplatin induced 18 and 23% apoptosis, respectively
(Figure 4), confirming that cell death occurs via apoptosis.
Titanocenes X and Y induce cell cycle arrest in A431 cells
The mechanism of action of titanocenes in tumour cells is
unknown. To investigate their mechanism of action, the effect of
titanocenes on cell cycle progression of A431 and HeLa cells was
analysed, and this was compared to Cp2TiCl2 and cisplatin. As
shown, untreated and vehicle-treated cells displayed a normal cell
cycle profile at 24-h (Figures 5A and C) and 48-h (Figures 5B and
D) following treatment. In contrast, treatment of A431 and HeLa
cells with cisplatin results in cell cycle arrest at S phase. Cell
cycle arrest, which is apparent following a 24-h treatment with the
drug, precedes the appearance of a pre-G1 peak at 48h that is
indicative of apoptosis in these cells. As indicated earlier, Cp2TiCl2
has little effect on A431 and HeLa cells and did not alter the cell
cycle profile significantly at 24 or 48h after treatment. An increase
in cells in G2/M was observed following Titanocene X treatment in
the A431 cells, but was less apparent in the HeLa cells. In contrast,
Titanocene Y caused the accumulation of cells in G2/M phase with
a concomitant decrease of cells in G1 phase of the A431 cell cycle at
24h (Figure 5A), which precedes the appearance of a pre-G1 peak
at 48h (Figure 5B). While cell cycle arrest was not apparent in
HeLa cells following treatment with Titanocene Y, an increased
pre-G1 peak was apparent at 48h following treatment (Figure 5D).
Overall, the cell cycle alterations observed with Titanocenes X and
Y differ from that observed following cisplatin treatment in A431
cells, and suggests that cisplatin and Titanocene compounds
initiate their apoptotic effects via alternative mechanisms.
Titanocene Y induces caspase activation in A431 cells
It has been previously reported that cisplatin-induced apoptosis in
A431 cells is mediated by the activation of caspases (Shapiro and
Harper, 1999). To characterise the apoptotic cell death pathway
activated by the most potent titanocene compound (Titanocene Y)
in A431 cells, we investigated the activity of caspases. Cells were
treated with Titanocene Y (50mM) for 24 and 48h or a range of
titanocene concentrations (0.5, 5.0 and 50mM) for 48h. Western
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Figure 3 Effect of Titanocene Y and cisplatin on growth of A431
xenograft mice in vivo. A431 cells (1 10
7) were injected subcutaneously
(s.c.) at day 0 into female NMRI:nu/nu mice (eight per group) allowed to
reach 5–6mm in diameter. Mice were treated i.p. with cisplatin
(3mgkgday
 1) or Titanocene Y (40mgkgday
 1) for 5 consecutive days
starting on day 8. For each treatment group, tumour volume was measured
using calipers on days 10, 14, 17 and 21 (A) and mean body weight was
calculated (B).
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sblot analysis to detect activated caspases illustrates that Titanocene
Y induces the time- and dose-dependent activation of caspase-3
and -7 in A431 cells (Figures 6A and B).
The general caspase inhibitor, z-VAD-fmk, blocks cell
death induced by Titanocene Y and cisplatin in A431 cells
To confirm the involvement of caspases during apoptosis, cells
were pretreated with the pan-caspase inhibitor, z-VAD-fmk, prior
to Titanocene Y or cisplatin, and apoptosis was determined by
flow cytometry following propidium iodide staining. Titanocene Y
and cisplatin alone induced 18 and 23% apoptosis, respectively.
However, pretreatment with z-VAD-fmk inhibits apoptosis
induced by Titanocene Y and cisplatin in A431 cells, confirming
that apoptosis occurs through a caspase-dependent pathway and
is in agreement with previous reports that z-VAD-fmk
blocked apoptosis induced by cisplatin in A431 cells (Sawada
et al, 2003).
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Figure 4 A431 cells undergo apoptosis when treated with Titanocene Y. Cells (0.8 10
6) were treated with (A) vehicle (DMSO (0.5% v/v)) or (B)
Titanocene Y (50mM)o r( C) cisplatin (50mM) for 48h. Cells were harvested by trypsination and centrifugation and stained with Annexin V/FITC antibody for
15min according to the manufacturer’s instructions. Cells were washed in binding buffer and stained with propidium iodide. Annexin V and propidium iodide
fluorescence was measured by flow cytometry.
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Figure 5 Effect of Cp2TiCl2, cisplatin, Titanocene X and Titanocene Y on A431 and HeLa cell cycle. A431 (A and B) and HeLa (C and D) cells
were treated with vehicle (DMSO) (0.5% v/v) or 50mM Cp2TiCl2, cisplatin, Titanocene X or Titanocene Y for (A and C) 24h and (B and C)4 8 h .
DNA was stained with propidium iodide, and DNA content was analysed by flow cytometry. Results represent the mean±s.e.m. of three separate
experiments.
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sDISCUSSION
Despite the widespread use of cisplatin as an antitumour agent, its
remarkable antitumour effects coincide with two major drawbacks
that have markedly limited cisplatin-based chemotherapy. These
include the marked toxic effects, such as neurotoxicity, nephro-
toxicity, severe emesis and the development of resistance to
platinum-based drugs (Siddik, 2003). Mechanisms of drug
resistance limit DNA damage through reduced drug uptake,
increased drug inactivation and increased DNA adduct repair. In
addition, tumour cells develop mechanisms to overcome death
signals, including the loss of p53 function, overexpression of
antiapoptotic Bcl-2 and interference with caspase activation
(Gonzalez et al, 2001; Siddik, 2003).
The development of new organometallic complexes with
lower toxicity and improved activity is important for improved
patient treatment options (Reedijk, 2003). In addition, alter-
native DNA damage-signalling pathways need to be evoked to
circumvent the development of drug resistance. This observation
has led to the synthesis of novel [(1,2-diaryl-1,2-dicyclopentadie-
nyl)ethanediyl] titanium dichlorides (Tacke et al, 2004), which
combine the reactivity of the titanium dichloride moiety with the
ability of hydrogen bonding towards DNA of the amine ligand of
cisplatin, if the aryl group is substituted accordingly. We have
shown that one member from this series, Titanocene X is
significantly more effective than titanium dichloride and exhibits
potent cytotoxic effect on kidney carcinoma cells and is cytotoxic
to cisplatin-resistant human ovarian carcinoma (Kelter et al, 2005).
The antitumour potential of novel titanocenes was further
demonstrated in freshly explanted human cervical carcinoma
cells and kidney cells (Oberschmidt et al, 2005), xenografted Caki-1-
bearing mice (Fichtner et al, 2006), xenografted Ehrlich’s ascites
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Figure 6 Western blot analysis of caspase-3, -7 and -8 following Titanocene Y treatment of A431 cells. Cells were treated with either vehicle (0.5%
DMSO (v/v)) or Titanocene Y (50mM) for (A) 24 or 48h or (B) a range of Titanocene Y concentrations (0–50mM) for 48h. Whole cell extracts were
prepared and protein (60mg) and resolved by SDS–PAGE followed by Western blotting using antibodies to detect the active cleavage product of caspase-3,
-7 and -8. As a positive control (þVE) for caspase 8 activity, PWR-1 prostate cells were treated with etoposide (10mM) for 48h. Blots were stripped and re-
probed with b-actin or GAPDH as loading controls. Results are representative of three independent experiments. (C) A431 cells (1 10
5 cells) were
treated with vehicle (DMSO (0.5% v/v)), 50mM Titanocene Y or 50mM cisplatin for 48h, or a pretreatment of z-VAD-fmk (150mM) for 1h prior to DMSO
(0.5% v/v) or 50mM Titanocene Y or cisplatin for a further 48h. Cell viability was determined by flow cytometry following propidium iodide staining. The
appearance of a pre-G1 peak represents non-viable cells. *Po0.005 with respect to cisplatin treatment, Student’s t-test. Results represent the mean±s.e.m.
of three separate experiments.
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stumours (Valadares et al, 2006) and MCF-7 xenografted mouse
model of breast cancer (Beckhove et al, 2007). The dose-dependent
effects observed in these in vivo models of human disease
demonstrate the lack of general toxicity exerted by highly
substituted titanocenes in tumour cells and suggest a tumour-
specific effect. Furthermore, previous studies indicate that
titanocenes have potent, broad spectrum antiproliferative
activity against a range of human tumour cells, including
multidrug-resistant cells and cells that overexpress the anti-
apoptotic Bcl-2, therefore suggesting the potential of this novel
range of compound for treating drug-refractory cancers (Kelter
et al, 2005; O’Connor et al, 2006). In the current study, we have
demonstrated that titanocenes cause dose- and time-dependent
antiproliferative effects in HeLa and A431 cells. The most
significant results were observed with Titanocene Y, which was
more effective than cisplatin at reducing proliferation of
A431 cells. On the basis of this observation, the effect of
Titanocene Y and cisplatin was investigated in an A431 xenograft
mouse model. Results clearly illustrate that Titanocene Y is as
effective as cisplatin at reducing tumour cell growth in vivo at their
respective maximum tolerable dose, when compared to solvent-
treated animals. In addition, there was no significance difference in
loss of body weight in animal groups treated with the two
compounds.
Cisplatin induces a combination of apoptosis and necrosis in
human tumour cells (Gonzalez et al, 2001; Reedijk, 2003). Necrosis
may occur directly as a result of cisplatin treatment depending
on the level of cellular damage induced or as a consequence of
an unfinished apoptotic programme (Gonzalez et al,2 0 0 1 ) .
Alternatively, the induction of necrosis may reflect the non-specific
toxicity often associated with cisplatin treatment. A precise
description of the mechanism of action of titanocenes is important
to determine their suitability in the treatment of various tumour
cells in addition to their suitability in combination treatment
regimens. We have confirmed that Titanocene Y-induced cell death
occurs via apoptosis as shown by Annexin V-positive staining.
The precise mechanism of action of agents such as cisplatin and
its analogues is not fully understood; however, it is closely related
to their DNA-binding effects. Cellular effects include inhibition
of DNA synthesis and RNA transcription, which leads to the
activation of cell cycle checkpoints and transient S-phase arrest
followed by a durable G2/M arrest (Shi et al, 1994; Shapiro and
Harper, 1999; Gonzalez et al, 2001; Reedijk, 2003; Siddik, 2003). In
this study, we investigated the cell cycle effects of novel
Titanocenes X and Y. Consistent with previous reports, cisplatin
induced S-phase arrest of A431 cells, which preceded apoptosis as
shown by the appearance of a sub-G1 peak. Cp2TiCl2 failed to
induce any significant cell cycle alterations or cell death in A431 or
HeLa cells at the concentration used, whereas Titanocene X caused
a small increase of cells in G2/M, with a concomitant induction of
apoptosis. However, the most potent compound, Titanocene Y
induced early G2/M arrest of A431 cells, which was followed by
a significant increase in apoptotic cells. In addition to A431
cells, Titanocene Y and cisplatin induced apoptosis in HeLa
cervical carcinoma cells. These results clearly illustrate the more
potent cytotoxic activity of Titanocene Y over Titanocene X.
Evaluation of the cell cycle effects observed suggest that the DNA
damage initiated by cisplatin and titanocenes results in the
activation of diverse cell cycle response. An understanding of the
mode of action of titanocenes is important in refining the
therapeutic approaches that further enhance the antitumour
activity of these compounds. This understanding is also critical
for elucidating the mechanisms underlying the development of
drug resistance.
Although cisplatin-induced apoptosis occurs through caspase-
dependent and caspase-independent mechanisms (Gonzalez et al,
2001), caspase-dependent apoptosis has been reported for the
A431 cell line (Mese et al, 2000; Sawada et al, 2003). We examined
the involvement of caspases during Titanocene Y-induced
apoptosis in A431 cells. Caspase-3 and -7 are important down-
stream executioners of intrinsic and extrinsic apoptotic pathways,
whereas caspase-8 is an upstream caspase that plays a key role
during death receptor-mediated apoptosis (Kasibhatla and Tseng,
2003; Vermeulen et al, 2005). We found that caspase-3 and -7 are
activated in a dose- and time-dependent manner during titano-
cene-induced apoptosis in A431 cells; however, we could not detect
activation of caspase-8. The z-VAD-fmk pan-caspase inhibitor
prevented apoptosis induced by cisplatin and Titanocene Y,
confirming the importance of caspases in the cell death process.
These results are consistent with the activation of an intrinsic non-
receptor-mediated apoptotic pathway in A431 cells. However,
these findings are in contrast to a previous report of caspase-
independent cell death induced by Titanocene Y in prostate cancer
cells (O’Connor et al, 2006), suggesting that titanocenes are
capable of inducing a number of cell death pathways. The precise
death pathway initiated appears to be cell type-specific and may
depend on the extent of the initial DNA damage induced in each
cell type. The specificity of titanocenes for apoptotic cell death may
represent an important advantage of these compounds over
cisplatin in cancer therapy.
Overall, we have described a new family of compounds that
show promising in vitro and in vivo antitumour activity and may
provide improved treatment options for the management of
metastatic and recurrent cancer.
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